The potential of protein kinase C as a target for anticancer treatment.

[1]  J. F. Day,et al.  Antineoplastic Components of Marine Animals , 1970, Nature.

[2]  J. Till,et al.  Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins. , 1977, Biochimica et biophysica acta.

[3]  Y. Nishizuka,et al.  Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. , 1977, The Journal of biological chemistry.

[4]  Y Nishizuka,et al.  Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. , 1977, The Journal of biological chemistry.

[5]  P. Blumberg,et al.  Specific binding of phorbol ester tumor promoters. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Y. Nishizuka,et al.  Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. , 1980, The Journal of biological chemistry.

[7]  Y Nishizuka,et al.  Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. , 1980, The Journal of biological chemistry.

[8]  M. Shoji,et al.  Substrate proteins for calmodulin-sensitive and phospholipid-sensitive Ca2+-dependent protein kinases in heart, and inhibition of their phosphorylation by palmitoylcarnitine. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y Nishizuka,et al.  Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. , 1982, The Journal of biological chemistry.

[10]  Isolation and structure of bryostatin 1 , 1982 .

[11]  J. J. Sando,et al.  Identification of high-affinity phorbol ester receptor in cytosol of EL4 thymoma cells: requirement for calcium, magnesium, and phospholipids. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Kuo,et al.  Modes of inhibition by acylcarnitines, adriamycin and trifluoperazine of cardiac phospholipid-sensitive calcium-dependent protein kinase. , 1983, Biochemical pharmacology.

[13]  J. Niedel,et al.  Phorbol diester receptor copurifies with protein kinase C. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Kraft,et al.  Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane , 1983, Nature.

[15]  D. Helfman,et al.  Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid. , 1983, Cancer research.

[16]  K. Leach,et al.  Competitive inhibition by diacylglycerol of specific phorbol ester binding. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Y. Nishizuka.  The role of protein kinase C in cell surface signal transduction and tumour promotion , 1984, Nature.

[18]  S. Kawamoto,et al.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. , 1984, Biochemistry.

[19]  Michael J. Berridge,et al.  Inositol trisphosphate, a novel second messenger in cellular signal transduction , 1984, Nature.

[20]  E. Rozengurt,et al.  Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. , 1984, Biochemical and biophysical research communications.

[21]  I. Weinstein,et al.  Inhibition of protein kinase C by tamoxifen. , 1985, Cancer research.

[22]  A. Kraft,et al.  Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. , 1985, Biochemical and biophysical research communications.

[23]  A. Kraft,et al.  Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Tamaoki,et al.  Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. , 1986, Biochemical and biophysical research communications.

[25]  F. Huang,et al.  Isozymic forms of rat brain Ca2+-activated and phospholipid-dependent protein kinase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Y. Nishizuka,et al.  [The role of protein kinase C in cell surface signal transduction and tumor promotion]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[27]  W. R. Bishop,et al.  Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. , 1986, The Journal of biological chemistry.

[28]  Y. Nishizuka.  Studies and perspectives of protein kinase C. , 1986, Science.

[29]  Y. Hannun,et al.  Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. , 1986, The Journal of biological chemistry.

[30]  I. Weinstein,et al.  Triphenylethylenes: a new class of protein kinase C inhibitors. , 1986, Journal of the National Cancer Institute.

[31]  C. Murakata,et al.  K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. , 1987, Biochemical and biophysical research communications.

[32]  W. Mellado,et al.  Phosphorylation of the multidrug resistance associated glycoprotein. , 1987, Biochemistry.

[33]  T. Tsuruo,et al.  Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. , 1987, Cancer research.

[34]  Y. Cheng,et al.  Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. , 1987, Cancer research.

[35]  R. Salem,et al.  Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Nelsestuen,et al.  Mechanism of protein kinase C inhibition by sphingosine. , 1987, Biochemical and biophysical research communications.

[37]  A. Wolfman,et al.  Elevated levels of diacylglycerol and decreased phorbol ester sensitivity in ras-transformed fibroblasts , 1987, Nature.

[38]  S. Yuspa,et al.  Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. , 1987, Carcinogenesis.

[39]  B. Kemp,et al.  Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. , 1987, Science.

[40]  P. Blumberg,et al.  Modulation by palmitoylcarnitine of protein kinase C activation. , 1987, Cancer research.

[41]  W. Hait,et al.  Inhibition of protein kinase C by antineoplastic agents: implications for drug resistance. , 1987, Biochemical and biophysical research communications.

[42]  M. Treat,et al.  Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas. , 1987, Cancer research.

[43]  M. Walsh,et al.  Properties and distribution of the protein inhibitor (Mr 17,000) of protein kinase C. , 1987, The Biochemical journal.

[44]  M. Baggiolini,et al.  The protein kinase inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranes. , 1988, Biochemical and biophysical research communications.

[45]  R. Bell,et al.  Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. , 1988, The Journal of biological chemistry.

[46]  P. Blumberg,et al.  Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. , 1988, Cancer research.

[47]  Y. Hannun,et al.  Aminoacridines, potent inhibitors of protein kinase C. , 1988, The Journal of biological chemistry.

[48]  Z. Kiss,et al.  Temporal changes in intracellular distribution of protein kinase C during differentiation of human leukemia HL60 cells induced by phorbol ester , 1988, FEBS letters.

[49]  W. Berdel,et al.  Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells. , 1988, Cancer research.

[50]  C. Piantadosi,et al.  Synthesis and evaluation of neoplastic cell growth inhibition of 1-N-alkylamide analogues of glycero-3-phosphocholine. , 1988, Journal of medicinal chemistry.

[51]  J. Darbon,et al.  Inhibition of MCF-7 cell growth by 12-O-tetradecanoylphorbol-13-acetate and 1,2-dioctanoyl-sn-glycerol: distinct effects on protein kinase C activity. , 1988, Cancer research.

[52]  R. Fine,et al.  Phorbol esters induce multidrug resistance in human breast cancer cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Grunicke,et al.  Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C , 1988, International journal of cancer.

[54]  Mark D. Johnson,et al.  Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts , 1988, Cell.

[55]  T. Takenawa,et al.  Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts. , 1988, The Journal of biological chemistry.

[56]  Y. Nishizuka,et al.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation , 1988, Nature.

[57]  W. Wilkison,et al.  Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA , 1988, Cell.

[58]  J. White,et al.  In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. , 1988, Cancer research.

[59]  F. Marks,et al.  Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. , 1988, Carcinogenesis.

[60]  P. Blumberg,et al.  Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations. , 1988, Cancer research.

[61]  N. Mazurek,et al.  A mutant protein kinase C that can transform fibroblasts , 1989, Nature.

[62]  T. Tamaoki,et al.  Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. , 1989, Biochemical and biophysical research communications.

[63]  D. Fabbro,et al.  A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity , 1989, International journal of cancer.

[64]  A. Kraft,et al.  Varied differentiation responses of human leukemias to bryostatin 1. , 1989, Cancer research.

[65]  I. Takahashi,et al.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. , 1989, The Journal of antibiotics.

[66]  Y. Hannun,et al.  The adriamycin-iron(III) complex is a potent inhibitor of protein kinase C. , 1989, The Journal of biological chemistry.

[67]  L. Magnelli,et al.  Synthesis of diacylglycerol de novo is responsible for permanent activation and down-regulation of protein kinase C in transformed cells. , 1989, Biochemical and biophysical research communications.

[68]  W. Anderson,et al.  Ca2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Y. Nishizuka,et al.  Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). , 1989, The Journal of biological chemistry.

[70]  P. Vichi,et al.  Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. , 1989, Cancer research.

[71]  A. Jetten,et al.  Effects of bryostatins and retinoic acid on phorbol ester- and diacylglycerol-induced squamous differentiation in human tracheobronchial epithelial cells. , 1989, Cancer research.

[72]  A. Malkinson,et al.  Altered function of protein kinase C and cyclic adenosine monophosphate-dependent protein kinase in a cell line derived from a mouse lung papillary tumor. , 1989, Cancer research.

[73]  Y. Nishizuka,et al.  Modes of inhibition of protein kinase C by triphenylacrylonitrile antiestrogens. , 1989, Biochemical and biophysical research communications.

[74]  S. Singletary,et al.  Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. , 1989, Cancer research.

[75]  T. Bradshaw,et al.  Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. , 1989, Cancer research.

[76]  C. Marshall,et al.  Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release, and arachidonic acid production by oncogenic ras is a consequence of protein kinase C activation. , 1989, The Journal of biological chemistry.

[77]  R. Epand,et al.  Inhibition of protein kinase C by sphingosine correlates with the presence of positive charge. , 1989, Biochemical and biophysical research communications.

[78]  I. Weinstein,et al.  Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene , 1989, Molecular and cellular biology.

[79]  I. Takahashi,et al.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. , 1989, The Journal of antibiotics.

[80]  C. Hensey,et al.  Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A , 1989, FEBS letters.

[81]  I. Pollack,et al.  Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. , 1990, Cancer research.

[82]  D. Baltimore,et al.  Activation in vitro of NF-κB" by phosphorylation of its inhibitor IκB" , 1990, Nature.

[83]  M. Ueffing,et al.  Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium. , 1990, Cancer research.

[84]  K. D. Hartman,et al.  Protein kinase C-γ is present in adriamycin resistant HL-60 leukemia cells , 1990 .

[85]  K. Ohmi,et al.  Effect of K252a, a protein kinase inhibitor, on the proliferation of vascular smooth muscle cells. , 1990, Biochemical and biophysical research communications.

[86]  D. Lester.  In vitro linoleic acid activation of protein kinase C. , 1990, Biochimica et biophysica acta.

[87]  A. Kraft,et al.  Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. , 1990, Cancer research.

[88]  D. Marquardt,et al.  Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. , 1990, The Journal of biological chemistry.

[89]  H. Grunicke,et al.  Enhancement of the antiproliferative activity of cis‐diamminedichloroplatinum(II) by quercetin , 1990, International journal of cancer.

[90]  A. Toker,et al.  Protein kinase C inhibitor proteins. Purification from sheep brain and sequence similarity to lipocortins and 14-3-3 protein. , 1990, European journal of biochemistry.

[91]  M. Hagiwara,et al.  Assessment of protein kinase C isozymes by enzyme immunoassay and overexpression of type II in thyroid adenocarcinoma. , 1990, Cancer research.

[92]  E. Melloni,et al.  A vincristine-resistant murine erythroleukemia cell line secretes a differentiation enhancing factor. , 1990, Biochemical and biophysical research communications.

[93]  S. Akinaga,et al.  Calphostin (UCN1028) and calphostin related compounds, a new class of specific and potent inhibitors of protein kinase C. , 1990, Advances in second messenger and phosphoprotein research.

[94]  B. Teicher,et al.  Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). , 1990, The Journal of biological chemistry.

[95]  T. Sugimura,et al.  Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin. , 1990, Cancer research.

[96]  T. Soderling.  Protein kinases. Regulation by autoinhibitory domains. , 1990, The Journal of biological chemistry.

[97]  T. Chambers,et al.  Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. , 1990, Biochemical and biophysical research communications.

[98]  T. Chambers,et al.  Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. , 1990, The Journal of biological chemistry.

[99]  R. Heinrikson,et al.  Amino acid sequence and characterization of a protein inhibitor of protein kinase C. , 1990, The Journal of biological chemistry.

[100]  I. Takahashi,et al.  Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. , 1990, The Journal of pharmacology and experimental therapeutics.

[101]  M. Diaz-Meco,et al.  Evidence for a role of phosphatidylcholine‐hydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes. , 1990, The EMBO journal.

[102]  C. Piantadosi,et al.  Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties. , 1990, Journal of medicinal chemistry.

[103]  T. Tsuruo,et al.  Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. , 1990, Biochemical and biophysical research communications.

[104]  J. Darbon,et al.  Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. , 1990, Cancer research.

[105]  S. Howell,et al.  Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. , 1990, The Journal of biological chemistry.

[106]  H. Drexler,et al.  Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia. , 1990, Leukemia.

[107]  C. Piantadosi,et al.  Synthesis and biological activity of novel quaternary ammonium derivatives of alkylglycerols as potent inhibitors of protein kinase C. , 1990, Journal of medicinal chemistry.

[108]  O. Hatase,et al.  Induction of differentiation of HL-60 cells by protein kinase C inhibitor, K252a. , 1990, Biochemical and biophysical research communications.

[109]  I. Weinstein,et al.  Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression , 1990, Molecular and cellular biology.

[110]  T. Tamaoki,et al.  Potent and Specific Inhibitors of Protein Kinase C of Microbial Origin , 1990, Bio/Technology.

[111]  J. Herbert,et al.  Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. , 1990, Biochemical and biophysical research communications.

[112]  L. Takemoto,et al.  Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. , 1991, The Journal of biological chemistry.

[113]  J. Howbert,et al.  Inhibition of protein kinase C by calphostin C is light-dependent. , 1991, Biochemical and biophysical research communications.

[114]  N. Ward,et al.  Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells. , 1991, Cancer letters.

[115]  F. Schildberg,et al.  Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. , 1991, Cancer research.

[116]  S. Hakomori,et al.  Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. , 1991, Cancer research.

[117]  J. Ramsdell,et al.  Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation. , 1991, The Journal of biological chemistry.

[118]  D. Kufe,et al.  Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. , 1991, Biochemistry.

[119]  L. Schuchter,et al.  Successful treatment of murine melanoma with bryostatin 1. , 1991, Cancer research.

[120]  B. A. Hocevar,et al.  Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. , 1991, The Journal of biological chemistry.

[121]  S. Akinaga,et al.  Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. , 1991, Cancer research.

[122]  D. Kufe,et al.  Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine. , 1991, Cancer research.

[123]  I. Fidler,et al.  Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. , 1991, Biochemical pharmacology.

[124]  S. Yuspa,et al.  Staurosporine induces protein kinase C agonist effects and maturation of normal and neoplastic mouse keratinocytes in vitro. , 1991, Cancer research.

[125]  D. Mochly‐Rosen,et al.  Identification of intracellular receptor proteins for activated protein kinase C. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[126]  N. Saijo,et al.  Establishment of a human leukemia subline resistant to the growth‐inhibitory effect of 12‐o‐tetradecanoylphorbol 13‐acetate (TPA) and showing non‐P‐glycoprotein‐mediated multi‐drug resistance , 1991, International journal of cancer.

[127]  D. Rideout,et al.  A self-assembling protein kinase C inhibitor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[128]  C. Borner,et al.  Failure of wild-type or a mutant form of protein kinase C-α to transform fibroblasts , 1991, Nature.

[129]  F. Zunino,et al.  Protein kinase C activation by anthracyclines in swiss 3T3 cells , 1991, International journal of cancer.

[130]  D L Alkon,et al.  Arachidonic acid and diacylglycerol act synergistically to activate protein kinase C in vitro and in vivo. , 1991, Biochemical and biophysical research communications.

[131]  P. Davis,et al.  A novel conformationally restricted protein kinase C inhibitor, Ro 31‐8425, inhibits human neutrophil superoxide generation by soluble, particulate and post‐receptor stimuli , 1991, FEBS letters.

[132]  V. Stevens,et al.  Long-chain (sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[133]  A. Ullrich,et al.  Protein kinase C , 1987, Journal of cellular physiology. Supplement.

[134]  Y. Hannun,et al.  Arachidonic andcis‐unsaturated fatty acids induce selective platelet substrate phosphorylation through activation of cytosolic protein kinase C , 1991, FEBS letters.

[135]  J. Utsunomiya,et al.  Protein kinase C activity as marker for colorectal cancer , 1991, International journal of cancer.

[136]  H. Grunicke,et al.  Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. , 1991, Cancer research.

[137]  L. Verdonck,et al.  Alkyllysophospholipid ET‐18‐OCH3 acts as an activator of protein kinase C in HL‐60 cells , 1991, FEBS letters.

[138]  H. Coste,et al.  The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. , 1991, The Journal of biological chemistry.

[139]  G. Schwartz,et al.  Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate. , 1991, Cancer research.

[140]  J. Cummings,et al.  The role of protein kinase C and the phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells. , 1991, Biochemical pharmacology.

[141]  J. Lazo,et al.  Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A. , 1991, Cancer research.

[142]  W. Hait,et al.  Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. , 1991, Molecular pharmacology.

[143]  Tony Hunter,et al.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity , 1991, Cell.

[144]  W. Anderson,et al.  Reversible oxidative activation and inactivation of protein kinase C by the mitogen/tumor promoter periodate. , 1991, Archives of biochemistry and biophysics.

[145]  K. Suzuki,et al.  Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. , 1991, Cancer communications.

[146]  P. Lin,et al.  Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. , 1992, Cancer research.

[147]  Y. Hannun,et al.  Activation of protein kinase C by oleic acid. Determination and analysis of inhibition by detergent micelles and physiologic membranes: requirement for free oleate. , 1992, The Journal of biological chemistry.

[148]  M. Castagna,et al.  Tumorigenicity‐associated expression of protein kinase C isoforms in rhabdomyosarcoma‐derived cells , 1992, FEBS letters.

[149]  N. Ward,et al.  Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. , 1992, Molecular pharmacology.

[150]  K. Takagi,et al.  Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells. , 1992, Cancer letters.

[151]  A. Toker,et al.  Multiple isoforms of a protein kinase C inhibitor (KCIP-1/14-3-3) from sheep brain. Amino acid sequence of phosphorylated forms. , 1992, European journal of biochemistry.

[152]  S. Gollapudi,et al.  Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport. , 1992, Cancer letters.

[153]  Y. Nishizuka.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.

[154]  N. Davidson,et al.  Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. , 1992, Cancer research.

[155]  B. Strulovici,et al.  Constitutive presence of a catalytic fragment of protein kinase C epsilon in a small cell lung carcinoma cell line. , 1992, The Journal of biological chemistry.

[156]  J. A. Dunn,et al.  Aflatoxin-transformed C3H/10T1/2 cells overexpress protein kinase C and have an altered response to phorbol ester treatments. , 1992, Cancer research.

[157]  K. Suzuki,et al.  Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin. , 1992, Molecular pharmacology.

[158]  J. Sullivan,et al.  2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain. , 1992, Molecular pharmacology.

[159]  K. Lee,et al.  Antitumor agents. 134. New shiraiachrome-A- and calphostin-C-related perylene derivatives as cytotoxic and antiviral agents and inhibitors of protein kinase C. , 1992, Journal of medicinal chemistry.

[160]  Y. Nishizuka,et al.  Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[161]  H. Bear,et al.  Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. , 1992, Cancer research.

[162]  R. Epand,et al.  Dual modulation of protein kinase C activity by sphingosine. , 1992, Biochemical and biophysical research communications.

[163]  C. Borner,et al.  Expression of four protein kinase C isoforms in rat fibroblasts. Distinct subcellular distribution and regulation by calcium and phorbol esters. , 1992, The Journal of biological chemistry.

[164]  J. Tímár,et al.  Protein‐kinase‐C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization , 1992, International journal of cancer.

[165]  K. Miller,et al.  p65 fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. , 1992, Biochemistry.

[166]  Y. Nishizuka,et al.  Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[167]  J. Lazo,et al.  Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. , 1992, Cancer research.

[168]  C. Borner,et al.  Expression of four protein kinase C isoforms in rat fibroblasts. Differential alterations in ras-, src-, and fos-transformed cells. , 1992, The Journal of biological chemistry.

[169]  Chaudhary Pm,et al.  Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. , 1992 .

[170]  M. Wolfson,et al.  Elevated activities of protein kinase C and tyrosine kinase correlate to leukemic cell aggressiveness , 1992, International journal of cancer.

[171]  A. Newton,et al.  Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol. , 1992, The Journal of biological chemistry.

[172]  J. Karaszkiewicz,et al.  Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. , 1992, Cancer research.

[173]  D. Schlaepfer,et al.  Inhibition of protein kinase C by annexin V. , 1992, Biochemistry.

[174]  V. Alvaro,et al.  Protein kinase C activity and expression in normal and adenomatous human pituitaries , 1992, International journal of cancer.

[175]  J. Lazo,et al.  Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C. , 1992, Biochemistry.

[176]  T. Chambers,et al.  Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. , 1992, Molecular pharmacology.

[177]  A. Kraft,et al.  Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. , 1992, The Journal of biological chemistry.

[178]  D. Longo,et al.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. , 1992, Cancer research.

[179]  T. Bradshaw,et al.  Modulation by staurosporine of phorbol‐ester‐induced effects on growth and protein kinase C localization in a549 human lung‐carcinoma cells , 1992, International journal of cancer.

[180]  C. Lanzi,et al.  Lipid peroxidation, phosphoinositide turnover and protein kinase C activation in human platelets treated with anthracyclines and their complexes with Fe(III). , 1992, Biochemical pharmacology.

[181]  R. Weichselbaum,et al.  cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. , 1992, Cancer research.

[182]  S. Bultel,et al.  Induction of protein kinase C down‐regulation by the phorbol ester TPA in a calpain/protein kinase C complex , 1992, International journal of cancer.

[183]  D. Burns,et al.  Alterations in protein kinase C isozymes α and β2 in activated Ha-ras containing papillomas in the absence of an increase in diacyiglycerol , 1992 .

[184]  R. Davenport,et al.  Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells. , 1992, Biochimica et biophysica acta.

[185]  I. Fidler,et al.  Stable expression of a cDNA encoding rat brain protein kinase C-beta I confers a multidrug-resistant phenotype on rat fibroblasts. , 1992, Anticancer research.

[186]  D. Fabbro,et al.  Selective redistribution of protein kinase C isozymes by thapsigargin and staurosporine. , 1992, Carcinogenesis.

[187]  D. Fabbro,et al.  Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. , 1993, The Journal of biological chemistry.